|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.26 USD | -3.84% |
|
-0.51% | -12.26% |
| Apr. 25 | Sector Update: Health Care Stocks Drop in Afternoon Trading | MT |
| Apr. 25 | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
May 22 (Reuters) - Pfizer Inc's diabetes drug resulted in weight loss similar to that of Novo Nordisk's Ozempic in a mid-stage study testing it in patients with type 2 diabates, according to a study published in JAMA network.
Shares of Pfizer rose about 4% following the news. (Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 866.8 DKK | -1.35% | +0.48% | 556B | ||
| 25.26 USD | -3.84% | -0.51% | 143B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -12.26% | 143B | |
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -6.47% | 144B | |
| +2.07% | 123B |
PFIZER, INC. 
